An optimized version of prime editing technology raises the possibility of a one-time treatment for cystic fibrosis. In their 2019 paper, Liu’s team used prime editing to alter the gene mutations ...
Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...
-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- - ...
At the WIRED Health summit last week, Harvard biochemist and gene-editing pioneer David Liu said that later this year his lab plans to report on a single gene-editing strategy that could treat many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback